Losartan is Appropriate and Recommended for Hypertension in Patients with Gout
Losartan should be preferentially chosen as the antihypertensive agent for patients with gout because it provides dual benefits: effective blood pressure control and modest uric acid reduction through its unique uricosuric properties. 1
Why Losartan is the Preferred Choice
The 2017 EULAR guidelines explicitly recommend losartan for hypertension management in gout patients 1. This recommendation is based on losartan's unique mechanism among angiotensin II receptor blockers (ARBs)—it is the only ARB with clinically significant uricosuric effects 2.
Magnitude of Uric Acid Reduction
Losartan reduces serum uric acid by approximately 0.3 mg/dL (50 µmol/L) 3, 4, 5. While this effect is modest compared to dedicated urate-lowering therapies like allopurinol or febuxostat, it provides meaningful clinical benefit in specific contexts:
- Counteracts diuretic-induced hyperuricemia: Particularly valuable since thiazide and loop diuretics commonly raise uric acid levels and are frequent gout triggers 1, 6
- Reduces cardiovascular risk: Addresses both hypertension and the independent cardiovascular risk associated with hyperuricemia 7
- Complements comprehensive gout management: Works as part of an overall treatment strategy 8
Clinical Application Algorithm
When to Choose Losartan:
- Any hypertensive patient with established gout diagnosis 1, 9
- Hypertensive patients currently on thiazide or loop diuretics who develop gout - switch the diuretic if possible, and consider losartan as the replacement antihypertensive 1, 6
- Patients with borderline hyperuricemia at risk for gout 3
- Patients requiring antihypertensive therapy who have frequent gout flares
Dosing:
- Standard antihypertensive dosing: 50-100 mg once or twice daily 10, 11, 12
- The uric acid-lowering effect occurs at therapeutic antihypertensive doses
Critical Limitations and Caveats
Losartan is NOT a substitute for dedicated urate-lowering therapy (ULT) in patients who meet criteria for ULT 1, 8, 5. The 0.3 mg/dL reduction is insufficient as monotherapy for most gout patients who require:
- Serum uric acid target <6 mg/dL (360 µmol/L) for standard gout 1
- Target <5 mg/dL (300 µmol/L) for severe gout with tophi or chronic arthropathy 1
First-line ULT remains allopurinol (starting 100 mg daily, titrating upward), with febuxostat or uricosurics as alternatives 1, 8. Losartan can be used as an adjunctive component of a comprehensive ULT strategy 8.
Contraindications to Consider:
- Bilateral renal artery stenosis 10, 7
- Pregnancy 10, 11
- History of angioedema with ARBs 10, 11
- Do not combine with ACE inhibitors or direct renin inhibitors 10, 11
Practical Management Strategy
For patients on diuretics who develop gout:
- Discontinue the diuretic if clinically feasible 1, 6
- Switch to losartan as the antihypertensive agent 1, 9
- Consider calcium channel blockers as alternative or additional agents 1
- Initiate appropriate ULT (allopurinol) if patient meets criteria for ULT 1, 8
For newly diagnosed hypertensive patients with gout:
- Choose losartan as first-line antihypertensive 1, 9
- Avoid thiazide diuretics 1, 10
- Assess need for dedicated ULT based on gout severity, frequency of flares, presence of tophi, or radiographic changes 1
Evidence Quality
The recommendation for losartan in gout patients with hypertension carries Grade C evidence (expert consensus) in the EULAR guidelines 1, reflecting that while the uricosuric effect is well-documented, long-term RCTs specifically examining gout outcomes are limited 6. However, recent meta-analyses confirm consistent uric acid reduction across multiple studies 4, and the 2020 ACR guidelines conditionally recommend choosing losartan preferentially when feasible 9.
The 2012 and 2020 ACR guidelines support using agents with uricosuric effects (including losartan) as components of comprehensive ULT strategy 8, 9, though they emphasize this should not replace appropriate treat-to-target therapy with xanthine oxidase inhibitors when indicated.